Ropeginterferon Redefines Second-Line Therapy in High-Risk Essential Thrombocythemia – Hematology Frontier
Hematology Frontier shared a post on LinkedIn:
“SURPASS-ET Trial: Ropeginterferon Redefines Second-Line Therapy in High-Risk ET丨EHA 2025
At the EHA 2025 Annual Meeting, one of the most impactful Plenary Presentations came from Professor Harry Gill (University of Hong Kong, School of Clinical Medicine), who unveiled the long-awaited results of the Phase III SURPASS-ET trial.
The study, conducted across 59 research centers worldwide, confirmed that Ropeginterferon alfa-2b is superior to anagrelide in both efficacy and safety as a second-line treatment for high-risk Essential Thrombocythemia (ET).”
Halima Mourabit, Editor in Chief at Mediamedic, shared Hematology Frontier’s post, adding:
“At the EHA 2025 Annual Meeting, Professor Harry Gill (University of Hong Kong, School of Clinical Medicine) presented the highly anticipated results of the Phase III SURPASS-ET trial.
Spanning 59 research centers worldwide, the study demonstrated that Ropeginterferon alfa-2b outperforms anagrelide as a second-line therapy for patients with high-risk Essential Thrombocythemia (ET)—achieving superior outcomes in both efficacy and safety.
These findings mark a dual breakthrough, reshaping the treatment landscape for high-risk ET and setting a new benchmark in clinical practice.”
More posts featuring Hematology Frontier on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023